Establishing combination PAC‐1 and TRAIL regimens for treating ovarian cancer based on patient‐specific pharmacokinetic profiles using in silico clinical trials

Establishing combination PAC‐1 and TRAIL regimens for treating ovarian cancer based on patient‐specific pharmacokinetic profiles using in silico clinical trials

Abstract Ovarian cancer is commonly diagnosed in its late stages, and new treatment modalities are needed to improve patient outcomes and survival. We have recently established the synergistic effects of combination tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL) and procaspase activ...

Full description

Bibliographic Details
Main Authors: Olivia Cardinal, Chloé Burlot, Yangxin Fu, Powel Crosley, Mary Hitt, Morgan Craig, Adrianne L. Jenner
Format: Article
Language:English
Published: Wiley 2022-06-01
Series:Computational and Systems Oncology
Subjects:
granulosa cell tumor of the ovary
in silico clinical trials
mathematical modeling
ovarian cancer
PAC‐1
pharmacokinetics
Online Access:https://doi.org/10.1002/cso2.1035

Internet

https://doi.org/10.1002/cso2.1035

Similar Items